Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics
Genomic Vision is a molecular diagnostics and technology company specialized in the development of single DNA detection tools for research and in vitro diagnostics. The company was created in 2004 by the founder-researcher Aaron Bensimon, a doctor in molecular biology and head of the Genomic Instability Unit of the Institut Pasteur at the time.
The company’s technology combines Molecular Combing; isolation and linearization genomic DNA, with a unique targeting and detection strategy, the Genomic Morse Code. Molecular Combing is a proprietary technique to isolate and stretch individual DNA molecules over a chemically modified glass surface. The Genomic Morse Code fluorescently labels the target loci providing a characteristic colour-coded pattern to clearly visualize genes in the loci of interest. This innovative approach is used in research and diagnostics to detect structural variations in the genome which are potentially the origin of numerous debilitating or life threatening pathologies.
Genomic Vision aims to bring a new perspective to genetic testing and biomarker discovery by bridging the gap between examining large chromosomal abnormalities and small sequence changes. GV's technology fulfills unmet diagnostic and research needs by enabling the rapid and accurate identification of large DNA rearrangements implicated in genetic diseases and cancer.
Genomic Vision's mission is to create new standards in Oncogenetic and genetic disease testing for more efficient, individualized, predictive and preventive health care management. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX® FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests. In France, the FSHD test is used at La Timone Hospital in Marseille, since 2010. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014. The company’s headquarters and research facilities are located in Bagneux (Paris region), France.